公开(公告)号：US20220128562A1

公开(公告)日：2022-04-28

申请号：US17294475

申请日：2019-11-25

Applicant: Dana-Farber Cancer Institute, Inc. ,  The General Hospital Corporation ,  University of Kansas

Inventor： Rizwan Haq ,  David Fisher ,  Frank Schoenen

IPC: G01N33/574 ,  A61K31/18 ,  G01N33/68

Abstract: The present invention is based in part on the identification of biomarkers, including NQO1, NRF2 and KEAP1, predictive of cancer cell responsiveness to treatment with ML 329 or a derivative thereof.

公开(公告)号：US20220112339A1

公开(公告)日：2022-04-14

申请号：US17554056

申请日：2021-12-17

Applicant: University of Kansas

Inventor： Bala Subramaniam ,  Julian R. Silverman ,  Andrew M. Danby ,  Thomas Binder ,  Steffan Green

IPC: C08J3/00

Abstract: Methods of forming lignin prepolymers are provided. In an embodiment, such a method comprises adding an acid to an ozonized reaction mixture, the ozonized reaction mixture comprising ozonized lignin having a backbone, and aromatic monomers cleaved from a lignin, under conditions to react the cleaved aromatic monomers with the backbone of the ozonized lignin to form a lignin prepolymer. The methods may further comprise using the lignin prepolymer to form a lignin resin.

公开(公告)号：US20220105151A1

公开(公告)日：2022-04-07

申请号：US17495556

申请日：2021-10-06

Applicant: The University of Kansas

Inventor： Peter S. N. Rowe

IPC: A61K38/17 ,  A61P13/12

Abstract: A method of treating or inhibiting a kidney disorder can include administering a therapeutically effective amount of the ASARM peptide to provide a treatment for the kidney disorder (treat disease) and/or inhibit development of the kidney disorder (prophylactic). The kidney disorder can be selected from the group consisting of chronic kidney disease mineral bone disorder (CKD-MBD), calciphylaxis, nephrogenic systemic fibrosis (NSF), end stage renal disease, and combinations thereof. The therapy can include inhibiting vascular calcification (VC), hard tissue calcification, soft tissue calcification, mineralization, or combinations thereof in the subject with the ASARM peptide. A method of inhibiting mineralization can include administering a therapeutically effective amount of the ASARM peptide to provide a treatment for inhibit mineralization in the subject. A method of treating hyperphosphatemia can include administering a therapeutically effective amount of the ASARM peptide to a subject to provide a treatment for hyperphosphatemia.

公开(公告)号：US11274859B2

公开(公告)日：2022-03-15

申请号：US16768171

申请日：2018-12-10

Applicant: University of Kansas

Inventor： Theodore L. Bergman

IPC: F25B21/04

Abstract: Examples of heat exchanger systems for active radiative cooling are described. In one example, the system includes a heat exchanger and a spectrally selective surface material on at least one surface of the heat exchanger. The spectrally selective surface material exhibits high reflectivity at shorter wavelengths and high emissivity at longer wavelengths. The system can also include an active cooling system in some cases to actively transfer heat to the heat exchanger. The use of spectrally selective surfaces that operate at temperatures exceeding that of the outdoor ambient for which convective losses augment radiation losses have advantages over passive cooling, such as but not limited to: providing a better match to cooling loads, reducing the heat rejection surface area required to achieve a desired cooling rate, and increasing the heat transferred to deep space through the atmospheric window so as to simultaneously cool infrastructure, devices, buildings, and Earth.

公开(公告)号：US20220073999A1

公开(公告)日：2022-03-10

申请号：US17514724

申请日：2021-10-29

Applicant: The University of Kansas ,  Kansas State University Research Foundation

Inventor： Mei He

IPC: C12Q1/6886 ,  A61K47/69 ,  G01N33/574 ,  G01N33/543 ,  B03C1/015 ,  B03C1/30 ,  B01L3/00 ,  A61K49/00

Abstract: Methods for producing engineered exosomes and other vesicle-like biological targets, including allowing a target vesicle-like structure to react and bind with immunomagnetic particles; capturing the immunomagnetic particle/vesicle complex by applying a magnetic field; further engineering the captured vesicles by surface modifying with additional active moieties or internally loading with active agents; and releasing the engineered vesicle-like structures, such as by photolytically cleaving a linkage between the particle and engineered vesicle-like structures, thereby releasing intact vesicle-like structures which can act as delivery vehicles for therapeutic treatments.

公开(公告)号：US20220071705A1

公开(公告)日：2022-03-10

申请号：US17466780

申请日：2021-09-03

Applicant: University of Kansas

Inventor： Xinmai Yang ,  M Laird Forrest

IPC: A61B18/24 ,  A61F2/01

Abstract: A system for thrombolysis includes an optical energy source, an ultrasound transducer, and an optical conduit for insertion into a vessel. The optical conduit directs optical energy from the optical energy source to a target location at a terminal end of the optical conduit.

公开(公告)号：US20220056002A1

公开(公告)日：2022-02-24

申请号：US17416172

申请日：2019-12-20

Applicant: The University of Kansas

Inventor： Steven Allan Soper ,  Blake R. Peterson ,  Richard S. Givens

IPC: C07D311/16 ,  G01N33/547

Abstract: A photocleavable heterobifunctional linker can include a structure of Formula (A) wherein coumarin is any coumarin or coumarin derivative; R, R9, and R10 are each independently a chemical moiety; R1 is a hydrogen, protecting group, leaving group, substrate, or capture entity; R2 is a hydrogen, hydroxyl, halide, alkoxy, anhydride, amino, protecting group, leaving group, substrate, or capture entity; L1 is a sub-linker; and L2 is a sub-linker. A capture device can include the photocleavable bifunctional linker having a structure of Formula (A) as provide herein, wherein R1 is a substrate. A method of capturing a target substance can include: providing the capture device having the photocleavable bifunctional linker with the structure of Formula (A) and contacting a target substance to the capture moiety such that the target substance is captured. Irradiating the linker with light can cleave the linker, thereby releasing the target substance from the substrate.

公开(公告)号：US20220054255A1

公开(公告)日：2022-02-24

申请号：US17517027

申请日：2021-11-02

Applicant: The University of Kansas ,  The Children's Mercy Hospital

Inventor： Michael Detamore ,  Lindsey Ott ,  Robert Weatherly

IPC: A61F2/20 ,  A61L27/10 ,  A61F2/04 ,  A61L27/34 ,  A61L27/18 ,  A61L27/14

Abstract: An implant can include a plurality of polymeric fibers associated together into a fibrous body. The fibrous body is capable of being shaped to fit a tracheal defect and capable of being secured in place by suture or by bioadhesive. The fibrous body can have aligned fibers (e.g., circumferentially aligned) or unaligned fibers. The fibrous body can be electrospun. The fibrous body can have a first characteristic in a first gradient distribution across at least a portion of the fibrous body. The fibrous body can include one or more structural reinforcing members, such as ribbon structural reinforcing members, which can be embedded in the plurality of fibers. The fibrous body can include one or more structural reinforcing members bonded to the fibers with liquid polymer as an adhesive, the liquid polymer having a substantially similar composition of the fibers.

公开(公告)号：US20220024869A1

公开(公告)日：2022-01-27

申请号：US17226359

申请日：2021-04-09

Applicant: University of Kansas ,  University of South Florida

Inventor： Sanket Jaiprakash Mishra ,  Brian S.J. Blagg ,  Chad Anthony Dickey

IPC: C07D207/325 ,  A61P27/06 ,  A61P35/00 ,  C07D401/06

Abstract: The present technology provides compounds according to Formula I or Formula III as well as compositions including such compounds useful for the treatment of metastatic cancer and/or glaucoma.

公开(公告)号：US20220008474A1

公开(公告)日：2022-01-13

申请号：US17488702

申请日：2021-09-29

Applicant: The Children's Mercy Hospital ,  The University of Kansas

Inventor： Amara Seng ,  Ryan Fischer ,  Thomas Yankee ,  Mary Markiewicz ,  John Szarejko

IPC: A61K35/17 ,  C12N15/86 ,  C12N5/0783

Abstract: Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+ Helios+ eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system.